Columbia University

Virginia Commonwealth University

Other

Johns Hopkins University

Sanford Burnham Prebys Medical Discovery Institute

Corixa Corporation

Paul B Fisher

Devanand Sarkar

Swadesh K Das

Mitchell E Menezes

Zao-Zhong Su

Hongping Jiang

Luni Emdad

Dong-Chul Kang

Rahul V Gopalkrishnan

Jorge A Leon

Martin Gilbert Pomper

Maurizio Pellecchia

Paul Dent

Jun Wei

Bainan Wu

Surya K De

Praveen Bhoopathi

Timothy P Kegelman

Dequan Yu

Neil I Goldstein

Malavi Madireddi

Xiang-Yang Wang

Xiaofei Yu

Ruoqian Shen

Siddik Sarkar

Xiang-yang Wang

Jolene Windle

Zhao-zhong Su

Manny Bacolod

Dong-chul Kang

Rupesh Dash

Anjan K Pradhan

Leszczyniecka Magdalena

Ruoquian Shen

Upneet Sokhi

Yilong Sun

Mitchell D Menezes

In various aspects, the present disclosure provides polynucleotides encoding a fusion protein, as well as vectors, cells, and compositions comprising the same. In embodiments, the fusion protein includes an insulin signal peptide and an MDA-7/IL-24 protein. Methods of using the polynucleotides, vectors, cells, and compositions, such as in the treatment or prevention of cancer, are also provided.

MDA-7/IL-24 secretory variants and methods of use

Provided herein are, inter alia, compositions that bind to a PDZ1 domain of MDA-9/Syntenin (syndecan binding protein: SDCBP), thereby inhibiting MDA-9/Syntenin activity, and methods of use of same. The compositions and methods provided herein are useful for treating cancer and preventing cancer metastasis, particularly in cancers that have increased MDA-9/Syntenin expression.

Inhibitors of cancer invasion, attachment, and/or metastasis

A tropism modified cancer terminator virus (Ad.5/3-CTV; Ad.5/3-CTV-M7) has been found to have infectivity that is Coxsackie Adenoviral Receptor (CAR) independent. The Ad.5/3-CTV (Ad.5/3-CTV-M7) may be used alone or in combination with other therapeutic agents such as agents that augment reactive oxygen (ROS) production, HDAC inhibitors, MCL-1 inhibitors and Bcl-2 inhibitors to treat a variety of cancers particularly including malignant glioma (GBM), renal cancer, prostate cancer, and colorectal cancer.

Tropism modified cancer terminator virus (Ad.5/3 CTV;Ad.5/3-CTV-M7)

Methods of prognosing the outcome of cancer and/or cancer treatment are provided. The methods involve quantitating the level of methylation at a site that regulates expression of the mda-9/Syntenin gene, site cg17197774. High levels of methylation indicate a good prognosis whereas low levels of methylation indicate a poor prognosis and determination of these levels permits risk stratification of patients with cancer.

Methylation site regulating expression of mda-9/syntenin

Tropism modified cancer terminator virus (Ad.5/3 CTV;AD.5/3-CTV-M7)

The presently disclosed subject matter generally relates to genetic constructs and methods for their use in cancer imaging, cancer treatment, and combined imaging and treatment protocols. In particular, the presently disclosed subject matter relates to tripartite cancer theranostic nucleic acid constructs that permit simultaneous cancer specific viral replication, expression of a diagnostic gene product, and expression of a therapeutic gene.

Tripartite cancer theranostic nucleic acid constructs

The presently disclosed subject matter relates to compositions and methods directed to cancer theranostic nucleic acid constructs that permit simultaneous cancer-specific viral replication, expression of a diagnostic gene product, and expression of a therapeutic gene.

[object Object]

Recombinant therapeutic cytokines ('therakines') for the treatment of cancer are provided. The recombinant therakines include a truncated region of MDA-7/TL-24 ('M4') not normally found in nature that has anti-cancer activity and a secretory signal which causes secretion of the therakine from plasmid/virus transduced normal and cancer cells and interaction of the therakine to MDA-7/IL-24 receptors on adjacent, neighboring and distant cancer cells. Therakine interaction results in bystander killing of the target cancer cell as well as adjacent, neighboring and distant cancer cells.

Recombinant cancer therapeutic cytokine

Recombinant vectors in which expression of one or more elements (e.g. genes required for viral replication, detectable imaging agents, therapeutic agents, etc.) is driven by a truncated CCN 1 cancer selective promoter (tCCN1-Prom) are provided, as are cells and transgenic animals that contain such vectors. The vectors are used in cancer therapy and/or diagnostics, and the transgenic mice are used to monitor cancer progression, e.g. in screening assays.

Use of a truncated CCN1 promoter for cancer diagnostics, therapeutics and theranostics

Recombinant vectors in which expression of one or more elements (e.g. gene required for viral replication, detectable imaging agents, therapeutic agents, etc.) is driven by an mda-9/syntenin (mda-9) cancer selective promoter are provided, as are cells and transgenic animals that contain such vectors. The vectors are used in cancer therapy and/or diagnostics, especially to visualize (image) and treat metastasis (including in rapid in vitro assays), and the transgenic mice are used to monitor cancer progression and/or the efficacy of candidate therapeutic agents in screening assays.

mda-9/syntenin promoter to image and treat metastatic cancer cells

A remote art jurying system in which art jurors independently evaluate works of art at different locations, times and places. A central database presents information about each work of art and/or the artist to an individual juror. The database provides images of the artwork along with relevant information. Each juror can access the database independent of other jurors in terms of location, or time. The system provides enhanced voting methods. The juror can review or change their votes at any time prior to final submission. They can review all works of art, by categories of art, or by scores. The juror reviews artwork thumbnail images, which can be used to select high resolution images with extended information. Selected categories of art can be enhanced by eliminating the lowest scores to balance artwork finalists across multiple categories of art. An online artist's application system is integrated with an image portfolio management system which allows artists to maintain permanent portfolio copies which can be electronically attached to applications. The system can be used for jurying art or other types of competitive ratings.

Asynchronous art jurying system

Inhibitors of Late SV-40 Factor (LSF) are used to treat cancers such as hepatocellular carcinoma (HCC). In particular, small molecule chemical LSF inhibitors are employed. In addition, the activity and/or pattern of expression of LSF may is used to diagnose cancer, to characterize the cancer (e.g. stage, grade, prognosis, etc.) and also to develop suitable protocols for cancer treatment.

Treatment of cancer by inhibiting activity or expression of late SV-40 factor

This invention provides a method for reversing the cancerous phenotype of a cancer cell by introducing a nucleic acid having the melanoma differentiation associated gene (mda-7) into the cell under conditions that permit the expression of the gene so as to thereby reverse the cancerous phenotype of the cell. This invention also provides a method for reversing the cancerous phenotype of a cancer cell by introducing the gene product of the above-described gene into the cancerous cell so as to thereby reverse the cancerous phenotype of the cell. This invention also provides a pharmaceutical composition having the melanoma differentiation associated gene (mda-7) or the gene product of the melanoma differentiation associated gene (mda-7) effective to reverse the cancerous phenotype of a cancer cell and a pharmaceutically acceptable carrier.

Methods of treating various cancers using melanoma differentiation associated protein-7

Growing community of inventors

Scarsdale, NY, United States of America

Paul B Fisher